{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:39:27Z","timestamp":1792172367386,"version":"4.4.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013059","name":"Jiangsu Provincial Medical Youth Talent","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013059","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>We report a case of non-bacterial cystitis after treatment with programmed death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) antibodies, which was considered an immune-related adverse event (irAE). A 48-year-old male patient with intrahepatic cholangiocarcinoma (ICC) was treated with nivolumab after postoperative multi-line treatment. This patient recurred worsening of psoriasis and repeated urinary tract discomfort. The drug was discontinued and surgery was performed due to the recurrence of the tumor suggested by imaging. After receiving three cycles of chemotherapy treatment combined with atezolizumab, urinary tract discomfort reappeared. No bacteria were found in multiple urine cultures, and non-bacterial bladder inflammation was considered after cystoscopy biopsy. This is a report of non-bacterial inflammation of the urinary tract caused by immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2021.788629","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T09:41:02Z","timestamp":1640252462000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors"],"prefix":"10.3389","volume":"12","author":[{"given":"Sihui","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated With Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-20-338","article-title":"Pembrolizumab Combined With Lenvatinib as Non-First-Line Therapy in Patients With Refractory Biliary Tract Carcinoma","volume":"9","author":"Lin","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-017-0298-6","article-title":"A Case of Cystitis After Administration of Nivolumab","volume":"6","author":"Ozaki","year":"2017","journal-title":"Int Cancer Conf J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2017.12.006","article-title":"Two Cases of Nonbacterial Cystitis Associated With Nivolumab, the Anti-Programmed-Death-Receptor-1 Inhibitor","volume":"17","author":"Shimatani","year":"2018","journal-title":"Urol Case Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing Toxicities Associated With Immune Checkpoint Inhibitors: Consensus Recommendations From the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073","article-title":"Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Internal Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical Features, Predictive Correlates, and Pathophysiology of Immune-Related Adverse Events in Immune Checkpoint Inhibitor Treatments in Cancer: A Short Review","volume":"6","author":"Yoest","year":"2017","journal-title":"ImmunoTargets Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00018-005-5390-y","article-title":"Glucocorticoids in T Cell Apoptosis and Function","volume":"63","author":"Herold","year":"2006","journal-title":"Cell Mol Life Sci CMLS"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000360","article-title":"Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma","volume":"44","author":"Kartolo","year":"2021","journal-title":"J Immunother (Hagerstown Md 1997)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clinthera.2018.11.004","article-title":"Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients With Melanoma Treated With Nivolumab: A Multicenter Retrospective Study","volume":"41","author":"Okada","year":"2019","journal-title":"Clin Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96798","article-title":"Early B Cell Changes Predict Autoimmunity Following Combination Immune Checkpoint Blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0487","article-title":"The Balancing Act Between Cancer Immunity and Autoimmunity in Response to Immunotherapy","volume":"6","author":"Young","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-Related Adverse Events and Anti-Tumor Efficacy of Immune Checkpoint Inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-Related Adverse Events Predict the Therapeutic Efficacy of Anti-PD-1 Antibodies in Cancer Patients","volume":"109","author":"Rogado","year":"2019","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab: Long-Term Outcomes From a Multi-Institutional Analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2018.07.005","article-title":"[Physiopathological Mechanisms of Immune-Related Adverse Events Induced by Anti-CTLA-4, Anti-PD-1 and Anti-PD-L1 Antibodies in Cancer Treatment]","volume":"105","author":"Passat","year":"2018","journal-title":"Bull du Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Trans Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.788629\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T09:41:05Z","timestamp":1640252465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.788629\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2021.788629"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.788629","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"article-number":"788629"}}